State-of-the-art automated facility for development and manufacturing of Transdermal Drug Delivery Systems and Oral Thin Films with 40 million units/year capacity
Shilpa Medicare's Unit VI is a state-of-the-art, fully automated facility designed for the development and manufacturing of innovative drug delivery systems including Transdermal Patches (TDS) and Oral Thin Films (OTF).
Built to comply with all global regulatory standards, this facility represents our commitment to modern pharmaceutical delivery technologies that enhance patient compliance and therapeutic outcomes.
40 million products per year production capacity
Certified by GMP consultants meeting global regulatory standards
State-of-the-art automated production and quality control systems
Composed of mono or multi-layer polymeric matrix, OTF are modern drug delivery systems designed for comfort and compliance using water-based soluble polymers for rapid drug delivery.
Single or multi-layer polymeric adhesive matrix containing drug substance, sandwiched between backing film and release liner for sustained systemic drug delivery.
Multiple coating methods with flexible width capabilities
Specific and flexible packaging for diverse formats
High-tech precision converting ensures dose accuracy
The facility is fully equipped with state-of-the-art instruments to evaluate all types of testing requirements for both Oral Thin Films and Transdermal Patch formulations, ensuring consistent product quality and regulatory compliance.
Customer satisfaction is our top priority. We ensure client needs are met through high service standards for both existing and new products:
